Start Date
June 1, 2017
Primary Completion Date
February 24, 2018
Study Completion Date
February 24, 2018
Vemurafenib and Cobimetinib
All participants will receive study treatment for up to 56 days (8 weeks). After completing treatment, they will undergo a lymph node removal surgery. After surgery, they will have follow-up visit 2-4 weeks after surgery.
Inova Schar Cancer Institute, Fairfax
Lead Sponsor
Collaborators (1)
Genentech, Inc.
INDUSTRY
Inova Health Care Services
OTHER